Pr Andreas MANZ
Institute of Spectrochemistry and Applied Spectroscopy (ISAS),
Dortmund and Berlin, Germany
"the history and novel concepts for Miniaturized Total Analysis Systems" (provisional title)

Professor Manz is one of the pioneers in microchip technology used for chemical applications. He was involved in the development of high speed analysers based on capillary electrophoresis, liquid chromatography and chemical binding. These analysers profit from the microfabrication know-how originally developed for microelectronics, from the small volumes obtainable, and from the high degree of integration. He did most of his previous research with his group at Ciba-Geigy Ltd. in Basel, Switzerland and at Imperial College in London, U.K. He developed a novel concept for Miniaturized Total Analysis Systems (µ-TAS): sampling, any sample pretreatment, separation, and detection steps are all performed in an integrated microsystem. A chemical parameter, for example the concentration of a compound, is periodically transformed into an electronic or an optical signal. In fact, it is a hybrid combining the advantages of a sophisticated analysis system with the size of a chemical sensor.

Pr Stefan MATILE
Geneva University, Switzerland
"the latest development and expectation in supramolecular chemistry in the perspective of bio to nano applications " (provisional title)

Stefan Matile received Diploma (1989) and PhD from the University of Zurich (1994) for research in bioorganic porphyrin chemistry in the group of Wolf Woggon. After a postdoc with Koji Nakanishi at Columbia University on circular dichroism spectroscopy (1994-1996), he first joined the faculty of Georgetown University (1996-1999) and then the University of Geneva. This research interests are at the interface of synthetic, biological and materials chemistry.

Pr Lars MONTELIUS
Lund University, Sweden
"bio – non bio inteface in bionic applications" (provisional title)

Professor and Dean of Physics Department, Lund University, Sweden. After his thesis defense 1987 he spend a Post-doc year at IBM, Yorktown Heights working with Scanning Probe Microscopy. 1989 appointed as Head of the Nanometer Laboratory at Lund University. His primary research interests are on exploratory nano-technology bringing nanotechnology to the life sciences: brain machine interfaces, nanochip protein traffic systems and sensor systems. LM has more than 16 years of experience with nanotechnology and he holds 13 patents, published more than 110 articles and given roughly 50 invited talks. LM has transferred technology to Obducat AB, Malmö, and he is a director of the board. He is also the founder of several Ideon nanotech companies.

Vasilis NTZIACHRISTOS
Harvard Medical School, USA
"Latest development and future innovation in in vivo molecular imaging" (provisional title)

Vasilis Ntziachristos Ph.D. is an Assistant Professor at Harvard University Medical School and the Massachusetts General Hospital and head of the Laboratory for Biooptics and Molecular Imaging at the Center for Molecular Imaging Research. He has received his masters and doctorate degrees from the Bioengineering Department of the University of Pennsylvania and the Diploma on Electrical Engineering from the Aristotle University of Thessaloniki, Greece. His main research interests involve the development of optical methodologies for probing physiological and molecular events in tissues using non-invasive methods.

Pr Andreas JORDAN
La Charité, Berlin, Germany
MagForce, Berlin, Germany
"From the lab to the patient’s bed: use of nanoparticles for cancer therapy" (provisional title)

Dr. Jordan is a pioneer in nanotechnology based cancer therapy. He completed his doctorate in 1993 and invented the so-called nano-cancer therapy during two decades of academic research. In 1998, he founded the medtech company “MFH Hyperthermiesysteme GmbH”. Today´s product is the clinical magnetic field applicator for the new therapy. In 2000 Dr. Jordan founded the nanobiotech company MagForce Applications GmbH for the production and commercialization of tumor-specific nanoparticles. In 2001 the foundation of the MFH Magnetic Fluid Hyperthermia GmbH, a financial holding for the mutual commercialization of both product lines, followed. With the successful completion of the second financing round all three historically grown companies were united into the former financial holding and renamed in MagForce Nanotechnologies GmbH, commuted into MagForce Nanotechnologies AG in 2005. MagForce products will enter the EU-market in 2007. Dr. Jordan held more than 500 scientific lectures about his international recognized nanotechnology-based cancer therapy. He promoted several successful clinical studies and wrote 40 publications in peer reviewed journals and also smoothed the way for 12 international patent families.

THIS LIST IS UNCOMPLETE